This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
New Tool to Assess Digital Addiction in ... A new study developed and validated a tool for assessing ... (10 Dec 2019)
Study Reveals Increased Cannabis Use in ... The prevalence of cannabis, or marijuana, use in the United ... (10 Dec 2019)
Are Women Getting Adequate Nutrition During ... In a Maternal & Child Nutrition analysis of published ... (05 Dec 2019)
Exposure to Smoking in Early Childhood ... In a recent study, children exposed to smoking in the first 4 ... (05 Dec 2019)
Social Media Use and Disordered Eating in ... New research suggests that social media, particularly platforms ... (05 Dec 2019)
Rate this item
(0 votes)
The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Mazza A 1, Schiavon L , Rigatelli G , Torin G , Montanaro F , Lenti S . Background - The clinical hypocholesterolemic effect of nutraceutical compounds (NCs) containing red yeast rice extracts providing a daily dose of 2.5-10 mg of monacolin K is now well established. For this reason, NCs may be a viable alternative to the statin drugs commonly used to lower cholesterol levels. However, in order to avoid some possible statin-like side effects, most NCs available on the market contain low doses of monacolin K, which could reduce their efficacy. The aim of this study was to investigate the efficacy and safety of a NC containing high doses of monacolin K (10 mg) in improving the lipid profile and glucose metabolism when added to the diet versus the diet alone in a group of hypertensive and hyper-cholesterolemic subjects at low cardiovascular risk. Methods - Thirty subjects with grade-1 essential hypertension (mean age 51.5 ± 7.8 years, 62.9% males) were enrolled in the treatment group (NC group). These subjects followed a programmed diet and took one tablet…
Rate this item
(2 votes)
Meningococcal Group B (MenB) is Responsible for 60 Percent of Meningococcal Disease Cases in Adolescents and Young Adults in Europe[1]  
Rate this item
(0 votes)
On the 15th June, a new glaucoma procedure was performed for the first time in Malta, as part of a surgeon training session organised by Allergan. The new XEN implant forms part of Allergan’s Eyecare portfolio distributed by Vivian Corporation.
Page 1 of 2

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…